West Pharmaceutical Services (NYSE: WST) reported Q1 2025 financial results with net sales of $698.0 million, showing a 0.4% increase and 2.1% organic growth. The company's reported-diluted EPS was $1.23, down from $1.55 year-over-year, while adjusted-diluted EPS reached $1.45.
The company has raised its full-year 2025 guidance, with net sales now projected at $2.945-2.975 billion, up from previous $2.875-2.905 billion. The adjusted-diluted EPS guidance was increased to $6.15-6.35, incorporating estimated tariff costs of $20-25 million.
In Q1, Proprietary Products segment saw 0.6% growth to $563.0 million, while Contract-Manufactured Products declined 0.7% to $135.0 million. The company repurchased 550,281 shares for $133.5 million and declared a Q3 2025 dividend of $0.21 per share, payable August 6, 2025.
Thursday, April 24, 2025
West Announces First-Quarter 2025 Results, Increases Adjusted-Diluted EPS Guidance
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.